|
|
|
Insider
Information: |
Paul Steven M |
Relationship: |
|
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
1,185,025 |
|
Indirect Shares
|
632,151 |
|
|
Direct
Value |
$40,114,906 |
|
|
Indirect Value
|
$32,687,802 |
|
|
Total
Shares |
1,817,176 |
|
|
Total
Value |
$72,802,707 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Eli Lilly & Co |
LLY |
EVP, Science and Techn... |
2010-02-01 |
38,897 |
2010-02-01 |
39,040 |
Premium* |
|
Sigma-Aldrich Corp |
SIAL |
Director |
2015-11-18 |
0 |
2007-01-02 |
0 |
Premium* |
|
Sage Therapeutics, Inc. |
SAGE |
|
2019-03-21 |
272,777 |
2022-11-28 |
593,111 |
Premium* |
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
2022-04-01 |
1,000 |
2015-01-26 |
0 |
Premium* |
|
Voyager Therapeutics, Inc. |
VYGR |
President and CEO, Dir... |
2016-01-14 |
872,351 |
|
0 |
Premium* |
|
Karuna Therapeutics, Inc. |
KRTX |
|
2024-03-18 |
0 |
2024-03-18 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
131 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
LLY |
Eli Lilly & Co |
EVP, Science and TechnologyOff |
|
2003-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,504 |
|
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and TechnologyOff |
|
2003-07-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
42,150 |
|
- |
|
SAGE |
Sage Therapeutics, Inc. |
Director |
|
2014-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
793,650 |
|
- |
|
VYGR |
Voyager Therapeutics, Inc... |
President and CEOOfficer |
|
2015-11-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
862,351 |
|
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2003-12-16 |
5 |
GD |
$0.00 |
$0 |
I/I |
216 |
28,661 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2003-12-17 |
5 |
GD |
$0.00 |
$0 |
I/I |
213 |
28,448 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2004-04-13 |
5 |
GD |
$0.00 |
$0 |
I/I |
109 |
38,843 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2004-06-02 |
5 |
GA |
$0.00 |
$0 |
I/I |
1,383 |
40,226 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2004-06-02 |
5 |
GD |
$0.00 |
$0 |
D/D |
1,383 |
18,931 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2004-09-27 |
5 |
GA |
$0.00 |
$0 |
I/I |
10,314 |
50,540 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2004-09-27 |
5 |
GD |
$0.00 |
$0 |
D/D |
10,314 |
8,000 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2004-12-28 |
5 |
GD |
$0.00 |
$0 |
I/I |
234 |
50,306 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2005-05-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
86 |
16,914 |
|
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2005-07-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
87 |
16,827 |
|
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2005-10-14 |
4 |
GD |
$0.00 |
$0 |
I/I |
48,257 |
2,049 |
|
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2005-10-14 |
4 |
GA |
$0.00 |
$0 |
D/D |
48,257 |
76,919 |
|
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2005-12-23 |
5 |
GD |
$0.00 |
$0 |
D/D |
2,960 |
77,092 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2005-12-23 |
5 |
GA |
$0.00 |
$0 |
I/I |
2,960 |
4,836 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2006-09-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,070 |
39,656 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2006-09-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,070 |
5,906 |
0 |
- |
|
SIAL |
Sigma-Aldrich Corp |
Director |
|
2007-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,200 |
1,200 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2007-02-09 |
4 |
GA |
$0.00 |
$0 |
I/I |
14,579 |
15,649 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2007-02-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
14,579 |
40,040 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2007-05-30 |
5 |
GA |
$0.00 |
$0 |
I/I |
4,665 |
5,735 |
0 |
- |
|
LLY |
Eli Lilly & Co |
EVP, Science and Technology |
|
2007-05-30 |
5 |
GD |
$0.00 |
$0 |
D/D |
4,665 |
40,040 |
0 |
- |
|
131 Records found
|
|
Page 1 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|